As Carlyle Group LP (CG) Market Valuation Rose, American Financial Group Has Decreased by $4.23 Million Its Stake; Nektar Therapeutics (Call) (NKTR) Shareholder Artal Group Sa Has Trimmed Holding

January 14, 2018 - By wolcottdaily

American Financial Group Inc decreased its stake in Carlyle Group LP (CG) by 17.45% based on its latest 2017Q3 regulatory filing with the SEC. American Financial Group Inc sold 183,764 shares as the company’s stock rose 9.66% with the market. The institutional investor held 869,150 shares of the investment managers company at the end of 2017Q3, valued at $20.51M, down from 1.05 million at the end of the previous reported quarter. American Financial Group Inc who had been investing in Carlyle Group LP for a number of months, seems to be less bullish one the $8.46B market cap company. The stock increased 2.43% or $0.6 during the last trading session, reaching $25.3. About 732,460 shares traded. The Carlyle Group L.P. (NASDAQ:CG) has risen 10.76% since January 14, 2017 and is uptrending. It has underperformed by 5.94% the S&P500.

Artal Group Sa decreased its stake in Nektar Therapeutics (Call) (NKTR) by 40% based on its latest 2017Q3 regulatory filing with the SEC. Artal Group Sa sold 400,000 shares as the company’s stock rose 44.66% with the market. The institutional investor held 600,000 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $14.40 million, down from 1.00 million at the end of the previous reported quarter. Artal Group Sa who had been investing in Nektar Therapeutics (Call) for a number of months, seems to be less bullish one the $11.34 billion market cap company. The stock increased 3.03% or $2.12 during the last trading session, reaching $72. About 1.90M shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 41.52% since January 14, 2017 and is uptrending. It has outperformed by 24.82% the S&P500.

Investors sentiment decreased to 1.4 in 2017 Q3. Its down 0.49, from 1.89 in 2017Q2. It worsened, as 15 investors sold NKTR shares while 52 reduced holdings. 26 funds opened positions while 68 raised stakes. 148.76 million shares or 1.09% more from 147.16 million shares in 2017Q2 were reported. Natl Bank Of New York Mellon Corp reported 2.06 million shares or 0.01% of all its holdings. Federated Inc Pa holds 0.07% or 1.03 million shares in its portfolio. Walleye Trading Limited Liability Com has invested 0% in Nektar Therapeutics (NASDAQ:NKTR). Rhumbline Advisers invested in 0.02% or 317,292 shares. Leisure Mngmt, California-based fund reported 10,367 shares. Winslow Evans & Crocker accumulated 300 shares. 1.18 million are owned by Price T Rowe Assoc Md. Paradigm Asset Limited Liability Corp owns 3,250 shares for 0.02% of their portfolio. University Of Notre Dame Du Lac reported 131,757 shares stake. Us Bancshares De, a Minnesota-based fund reported 93,340 shares. Franklin Street Inc Nc has 58,000 shares for 0.23% of their portfolio. State Of New Jersey Common Pension Fund D holds 0.01% or 105,000 shares. Northwestern Mutual Wealth holds 0% or 200 shares. Everence Capital Incorporated reported 10,150 shares stake. State Street Corp invested in 3.97M shares.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on March, 7. They expect $-0.35 EPS, down 25.00% or $0.07 from last year’s $-0.28 per share. After $0.37 actual EPS reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -194.59% negative EPS growth.

Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 21 analyst reports since August 6, 2015 according to SRatingsIntel. Jefferies maintained Nektar Therapeutics (NASDAQ:NKTR) rating on Wednesday, November 8. Jefferies has “Buy” rating and $35.0 target. The firm has “Buy” rating by Roth Capital given on Monday, November 13. On Wednesday, August 9 the stock rating was maintained by Roth Capital with “Buy”. The rating was maintained by Canaccord Genuity on Wednesday, January 10 with “Buy”. The firm has “Buy” rating by J.P. Morgan given on Tuesday, July 18. Jefferies maintained the stock with “Buy” rating in Wednesday, October 18 report. Roth Capital maintained it with “Buy” rating and $3100 target in Tuesday, May 30 report. The company was initiated on Tuesday, November 8 by Aegis Capital. The rating was downgraded by TheStreet on Wednesday, August 26 to “Hold”. Aegis Capital maintained Nektar Therapeutics (NASDAQ:NKTR) on Monday, June 5 with “Buy” rating.

Artal Group Sa, which manages about $5.81B US Long portfolio, upped its stake in Incyte Corp (NASDAQ:INCY) by 200,000 shares to 400,000 shares, valued at $46.70 million in 2017Q3, according to the filing. It also increased its holding in Bluebird Bio Inc (NASDAQ:BLUE) by 85,000 shares in the quarter, for a total of 135,000 shares, and has risen its stake in Array Biopharma Inc (NASDAQ:ARRY).

Since August 16, 2017, it had 0 insider purchases, and 18 insider sales for $19.24 million activity. Labrucherie Gil M also sold $61,380 worth of Nektar Therapeutics (NASDAQ:NKTR) on Wednesday, August 16. 4,000 shares were sold by KUEBLER CHRISTOPHER A, worth $87,440. Gergel Ivan P. sold $2.41 million worth of stock. The insider Doberstein Stephen K sold 43,677 shares worth $1.09M. 7,583 Nektar Therapeutics (NASDAQ:NKTR) shares with value of $189,575 were sold by Hora Maninder. Another trade for 3,177 shares valued at $61,380 was sold by Nicholson John.

Since August 2, 2017, it had 0 buys, and 4 insider sales for $1.32 million activity. $377,400 worth of The Carlyle Group L.P. (NASDAQ:CG) was sold by Bentley Pamela L on Wednesday, August 2. Ferguson Jeffrey W. had sold 16,692 shares worth $354,705 on Wednesday, August 2. Shares for $140,101 were sold by Mathias Edward J on Wednesday, August 2.

Investors sentiment decreased to 1.71 in Q3 2017. Its down 0.07, from 1.78 in 2017Q2. It dived, as 17 investors sold CG shares while 28 reduced holdings. 34 funds opened positions while 43 raised stakes. 33.48 million shares or 3.19% more from 32.44 million shares in 2017Q2 were reported. Brown Advisory Inc has 20,982 shares. Edgemoor Investment Advsrs invested in 15,945 shares. Stelac Advisory Services Ltd Liability owns 6,145 shares for 0.04% of their portfolio. Lpl Fincl Lc reported 0.01% of its portfolio in The Carlyle Group L.P. (NASDAQ:CG). Amer Gp has invested 2.12% of its portfolio in The Carlyle Group L.P. (NASDAQ:CG). Royal Bancorporation Of Canada has invested 0% of its portfolio in The Carlyle Group L.P. (NASDAQ:CG). Baldwin Brothers Ma owns 12,900 shares for 0.05% of their portfolio. Hsbc Hldgs Public Limited Company owns 29,281 shares or 0% of their US portfolio. Stephens Inc Ar has 8,827 shares for 0.01% of their portfolio. Pnc Svcs Group holds 0% or 117,709 shares. Highlander Capital Mngmt Ltd Liability Company invested 0.08% in The Carlyle Group L.P. (NASDAQ:CG). Creative Planning holds 0% in The Carlyle Group L.P. (NASDAQ:CG) or 31,150 shares. Geode Management Limited Com holds 58,727 shares. Credit Suisse Ag invested 0% in The Carlyle Group L.P. (NASDAQ:CG). Qci Asset Incorporated holds 0% or 1,500 shares in its portfolio.

Among 13 analysts covering Carlyle (NASDAQ:CG), 7 have Buy rating, 0 Sell and 6 Hold. Therefore 54% are positive. Carlyle had 60 analyst reports since July 30, 2015 according to SRatingsIntel. Morgan Stanley maintained The Carlyle Group L.P. (NASDAQ:CG) on Tuesday, August 8 with “Overweight” rating. Barclays Capital maintained the shares of CG in report on Thursday, July 30 with “Equal Weight” rating. The firm earned “Outperform” rating on Friday, July 14 by Oppenheimer. The firm earned “Buy” rating on Thursday, June 22 by Keefe Bruyette & Woods. The firm has “Hold” rating by Jefferies given on Thursday, August 3. Keefe Bruyette & Woods maintained The Carlyle Group L.P. (NASDAQ:CG) rating on Wednesday, January 10. Keefe Bruyette & Woods has “Buy” rating and $30.0 target. Keefe Bruyette & Woods maintained the shares of CG in report on Thursday, September 28 with “Buy” rating. The rating was maintained by Credit Suisse with “Outperform” on Thursday, November 2. The firm has “Buy” rating given on Tuesday, December 20 by Citigroup. The stock has “Market Perform” rating by Keefe Bruyette & Woods on Thursday, April 28.

American Financial Group Inc, which manages about $968.72M US Long portfolio, upped its stake in Energy Transfer Partners Lp by 295,000 shares to 835,000 shares, valued at $15.27M in 2017Q3, according to the filing.

Analysts await The Carlyle Group L.P. (NASDAQ:CG) to report earnings on February, 14. They expect $0.39 EPS, up 1,850.00% or $0.37 from last year’s $0.02 per share. CG’s profit will be $130.43 million for 16.22 P/E if the $0.39 EPS becomes a reality. After $0.56 actual EPS reported by The Carlyle Group L.P. for the previous quarter, Wall Street now forecasts -30.36% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>